Compare CL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CL | REGN |
|---|---|---|
| Founded | 1806 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 68.8B |
| IPO Year | 2008 | 1995 |
| Metric | CL | REGN |
|---|---|---|
| Price | $87.70 | $801.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 25 |
| Target Price | $94.19 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 3.6M | 541.9K |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.51% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 1.67 | ★ 18.95 |
| Revenue | ★ $15,454,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $7.49 | $12.45 |
| Revenue Next Year | $3.28 | $10.13 |
| P/E Ratio | $52.94 | ★ $42.76 |
| Revenue Growth | 1.70 | ★ 20.82 |
| 52 Week Low | $74.55 | $541.00 |
| 52 Week High | $99.33 | $859.34 |
| Indicator | CL | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 51.96 |
| Support Level | $84.19 | $732.04 |
| Resistance Level | $89.34 | $818.06 |
| Average True Range (ATR) | 1.33 | 18.05 |
| MACD | -0.33 | -6.43 |
| Stochastic Oscillator | 3.48 | 28.56 |
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including nearly half from emerging regions. It also owns specialty pet food maker Hill's (almost one-fourth of sales), which sells the majority of its products through veterinarians and specialty pet retailers.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.